KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Net Cash Flow: 2016-2024

Historic Net Cash Flow for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to $20.3 million.

  • Amneal Pharmaceuticals' Net Cash Flow rose 441.26% to $155.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $162.3 million, marking a year-over-year increase of 1043.23%. This contributed to the annual value of $20.3 million for FY2024, which is 68.17% down from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Net Cash Flow of $20.3 million as of FY2024, which was down 68.17% from $63.8 million recorded in FY2023.
  • Amneal Pharmaceuticals' 5-year Net Cash Flow high stood at $193.3 million for FY2020, and its period low was -$215.8 million during FY2022.
  • Moreover, its 3-year median value for Net Cash Flow was $20.3 million (2024), whereas its average is -$43.9 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first surged by 403.36% in 2020, then tumbled by 146.82% in 2021.
  • Amneal Pharmaceuticals' Net Cash Flow (Yearly) stood at $193.3 million in 2020, then slumped by 146.82% to -$90.5 million in 2021, then tumbled by 138.53% to -$215.8 million in 2022, then skyrocketed by 129.57% to $63.8 million in 2023, then tumbled by 68.17% to $20.3 million in 2024.